Go Pro
NASDAQ:PRE

Prenetics Global Q2 2025 Earnings Report

Prenetics Global logo
$22.76 -0.21 (-0.91%)
Closing price 04:00 PM Eastern
Extended Trading
$22.77 +0.01 (+0.05%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Prenetics Global EPS Results

Actual EPS
-$0.82
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Prenetics Global Revenue Results

Actual Revenue
$17.68 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Prenetics Global Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Prenetics Global's Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Prenetics Global Earnings Headlines

Comparing Prenetics Global (NASDAQ:PRE) & Lifevantage (NASDAQ:LFVN)
Management just bought 2.8 million shares
Management just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 in one quarter. Institutions own about 83% of shares, including BlackRock's 32 million shares worth $716 million and Vanguard's 48 million shares worth nearly $1.1 billion. A new multi-year deal with Palantir adds an AI-driven edge to this energy producer's operations.tc pixel
Prenetics Global (NASDAQ:PRE) Coverage Initiated at Craig Hallum
See More Prenetics Global Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Prenetics Global? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prenetics Global and other key companies, straight to your email.

About Prenetics Global

Prenetics Global (NASDAQ:PRE) is a health sciences and genomics company focused on consumer health, clinical diagnostics and precision oncology. The company develops and commercializes genetic testing and related healthcare solutions intended to help individuals and clinicians better understand disease risk, make informed health decisions and support personalized care.

Prenetics is known for CircleDNA, a consumer genetic testing platform that provides information related to ancestry, wellness, nutrition, lifestyle and selected health risks. The company also provides clinical and oncology-focused testing services, including genomic analysis designed to support cancer treatment decisions and the development of personalized medicine.

Founded in 2014, Prenetics has served customers and healthcare organizations across markets including Asia, the United Kingdom and the United States. The company has expanded its capabilities through the development and acquisition of precision oncology and genomic testing businesses. Prenetics is led by founder and Chief Executive Officer Danny Yeung and is listed on the Nasdaq Stock Market under the symbol PRE.

View Prenetics Global Profile